We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Dr
Thomas
Hiemstra
End stage renal disease
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Vitamin D is essential for good health, because it helps our bodies to absorb calcium from the diet. There is a lot of evidence that having enough vitamin D can help prevent against many diseases, such as heart and blood vessel (cardiovascular) disease, bone diseases and cancer. Although vitamins generally come from the diet, in the case of vitamin D, the majority of people actually get most of it from sunlight. When the sun shines on our skin, a reaction in the body is triggered, causing the body to produce an active form of vitamin D called vitamin D3. Vitamin D deficiency is common patients with end stage renal disease (kidney failure), and is a strong predictor of death from cardiovascular disease, infection and cancer. Almost all kidney failure patients who are treated with dialysis are given pre-activated vitamin D to take, however this approach increases blood calcium concentrations which may be harmful, and even make vitamin D deficiency worse. International treatment guidelines therefore now recommend that kidney patients receive inactive vitamin D (cholecalciferol), since we now know that every organ activates its own vitamin D as required, even in patients with kidney failure. However, this is not currently used in the NHS as it has not yet been tested in a trial. The aim of this study is to test whether taking cholecalciferol supplements increases survival in UK dialysis patients.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
2015 Abstract results in http://doi.org/10.1186/1745-6215-16-S2-O15 (added 10/05/2021)
You can take part if:
You may not be able to take part if:
Current exclusion criteria as of 23/11/2017:1. Current treatment with high dose (>1,000IU/day) cholecalciferol or ergocalciferol in the last 30 days2. Persistent hypercalcaemia (>2.62 mmol/l on three separate and sequential occasions without precipitating cause)3. Life expectancy of less than 6 months4. Women who are pregnant / planning to become pregnant5. Hypersensitivity to colecalciferol or any of the excipients6. Not contributing, or willing to contribute, data to the UK Renal Registry (UKRR)
Previous exclusion criteria:1. Current treatment with high dose (>1,000IU/day) cholecalciferol2. Persistent hypercalcaemia (>2.62 mmol/l on three separate and sequential occasions without precipitating cause)3. Life expectancy of less than 6 months4. Women who are pregnant / planning to become pregnant5. Inability to provide informed consent6. Not contributing, or willing to contribute, data to the UK Renal Registry (UKRR)
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
This information has not yet been provided by the study team. You'll have an opportunity to discuss any risks and benefits that may be associated with this study prior to consenting to taking part.
Dr
Thomas
Hiemstra
The study is sponsored by Cambridge University Hospitals NHS Foundation Trust and funded by National Institute for Health Research.
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
